•
Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr. 2007 May 1;45(1):1-3. Pubmed• Hanumegowda, U., et al.: Chem. Res. Toxicol., 23, 749 (2010)
• Prasse, C., et al.: Environ. Sci. Technol., 44, 1728 (2010)
• Crimmins, M.T. et al., J.O.C., 1996, 61, 4192-4193, (synth, pmr, cmr, ir)
• Graul, A. et al., Drugs of the Future, 1998, 23, 1155-1167, (abacavir sulfate)
• Daluge, S.M., Antimicrob. Agents Chemother., 1997, 41, 1082-1093; 1099-1107, (pharmacol, activity)
• Olivo, H.F., J.C.S. Perkin 1, 1998, 391, 392, (synth, bibl)
• Hervey, P.S. et al., Drugs, 2000, 60, 447-479, (rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 602
• Pat. Coop. Treaty (WIPO), 1998, Glaxo, 98 52 949; CA, 130, 38645e, (abacavir sulfate)
• Pat. Coop. Treaty (WIPO), 1996, Wellcome Foundation, 96 06 844; CA, 125, 41774y, (succinate)
• Eur. Pat., 1991, Wellcome Foundation, 434 450; CA, 115, 208462c, (synth, pharmacol)
• Foster, R.H. et al., Drugs, 1998, 55, 729-736, (rev)
• Moyle, J.G., Curr. Opin. Infect. Dis., 2000, 13, 19
• Daluge, S.M. et al., Nucleosides Nucleotides, 2000, 19, 297-327, (synth)